Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders. IBS is characterized by recurrent chronic abdominal pain and altered bowel habits in the absence of organic damage. Although there are reviews and guidelines for treating IBS, the complexity and diversity...

Full description

Saved in:

Bibliographic Details
Published in:	Minerva gastroenterology Vol. 69; no. 1; p. 123
Main Authors:	Fiorini, Giulia, Saracino, Ilaria M, Pavoni, Matteo, Nipote, Bruno, Colucci, Raffaele, Capone, Pietro, Sannino, Angela, Forte, Fabrizio, DE Vergori, Emiliano, Brancaccio, Mario, Cesareo, Maurizio, Casella, Giovanni, Morreale, Gaetano C, Bonfrate, Leonilde, Portincasa, Piero, Vincenzi, Massimo, Cottone, Carmelo, Ormando, Vittorio M, Scalise, Natale, Lawson, Paulin F, Burattini, Osvaldo, Montale, Amedeo, Luzza, Francesco, Rossi, Mauro, Vanni, Riccardo, Bozzi, Rosamaria, Vincoli, Giuseppina, Stefani, Nicoletta, Borghi, Claudio, Vaira, Dino
Format:	Journal Article
Language:	English
Published:	Italy 01-03-2023
Subjects:	Abdominal Pain - drug therapy Abdominal Pain - etiology Chamomile Charcoal Chronic Pain Dietary Supplements Flower Essences Gastrointestinal Diseases Glycyrrhiza Humans Irritable Bowel Syndrome - complications Irritable Bowel Syndrome - drug therapy Mentha Probiotics Tryptophan
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders. IBS is characterized by recurrent chronic abdominal pain and altered bowel habits in the absence of organic damage. Although there are reviews and guidelines for treating IBS, the complexity and diversity of IBS presentation make treatment difficult. Treatment of IBS focuses on relieving symptoms as mild signs and symptoms can often be controlled by managing stress and by making changes in diet and lifestyle. The use of nutraceutical compounds has been advocated as a possible alternative treatment in patients with IBS. COLONIR (Omega Pharma Srl, Milan, Italy) may be an alternative or adjuvant treatment in patients with gastrointestinal symptoms. This study aimed to evaluate the effect of this new nutraceutical formulation in inducing symptoms remission and improve gastrointestinal habits. An initial cohort of 1004 consecutive patients referred to 25 different Units of Internal Medicine a/o Gastroenterology in Italy to perform colonoscopy for intestinal symptoms was asked to participate. Patients were treated for 2 months with two doses of nutraceuticals/day during meals namely COLONIR . Patients were assessed at baseline and after 2 months to evaluate the frequency and severity of gastrointestinal symptoms in the past seven days with a questionnaire based on ROMA IV criteria. After 2 months, 899 patients completed the follow-up. COLONIR achieved a statistically significant reduction of severity of symptoms in the study population without any documented side effects. These promising results, here reported, need to be confirmed, valuating the efficacy of COLONIR in relieving gastrointestinal symptoms in IBS patients in further studies.
ISSN:	2724-5365
DOI:	10.23736/S2724-5985.22.03282-X